CN Patent

CN112300194B — 一类稠环吡啶酮类化合物、制备方法和用途

Assigned to Shanghai Lingda Biomedical Co Ltd · Expires 2022-01-14 · 4y expired

What this patent protects

本发明公开了一类稠环吡啶酮类化合物、制备方法和用途。具体为一种如通式I所示的稠环吡啶酮类化合物、或其药学上可接受的盐、或其对映异构体、非对映异构体、互变异构体、溶剂化物、多晶型物或前药、其制备方法及在药学上的应用，其中各基团的定义如说明书中所述。

USPTO Abstract

本发明公开了一类稠环吡啶酮类化合物、制备方法和用途。具体为一种如通式I所示的稠环吡啶酮类化合物、或其药学上可接受的盐、或其对映异构体、非对映异构体、互变异构体、溶剂化物、多晶型物或前药、其制备方法及在药学上的应用，其中各基团的定义如说明书中所述。

Drugs covered by this patent

Patent Metadata

Patent number
CN112300194B
Jurisdiction
CN
Classification
—
Expires
2022-01-14
Drug substance claim
No
Drug product claim
No
Assignee
Shanghai Lingda Biomedical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.